Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.62 |
| ▸ | INSR | P06213 | 7/20 | 0.55 |
| ▸ | IGF1R | P08069 | 7/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17411243 | 0.87 | ALK (0.82) | ALKINSRIGF1RPTK2EGFR | |
| SCHEMBL18812805 | 0.82 | ALK (0.65) | ALKINSRIGF1REGFRMAPK9 | |
| SCHEMBL28703584 | 0.81 | ALK (0.51) | ALKINSRIGF1RPTK2EGFR | |
| SCHEMBL17410995 | 0.79 | ALK (0.70) | ALKINSRIGF1RPTK2EGFR | |
| SCHEMBL11919111 | 0.78 | ALK (0.81) | ALKINSRIGF1RPTK2EGFR | |
| SCHEMBL17410895 | 0.77 | ALK (1.00) | ALKINSRIGF1RPTK2EGFR | |
| SCHEMBL28690880 | 0.76 | ALK (0.48) | ALKINSRIGF1RPTK2 | |
| SCHEMBL28703587 | 0.76 | PTK2 (0.45) | ALKINSRIGF1RPTK2 | |
| SCHEMBL18831896 | 0.74 | EGFR (0.63) | ALKINSRIGF1REGFRMET | |
| SCHEMBL28710161 | 0.74 | ALK (0.60) | ALKINSRIGF1RPTK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3165530-B1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QILU PHARMACEUTICAL CO LTD (CN) | 2018-12-05 | — | — | EP | disclosed |
| US-10053477-B2 | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide | QILU PHARMACEUTICAL CO., LTD. (CN) | 2018-08-21 | — | — | US | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| EP-3165530-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | Qilu Pharmaceutical Co., Ltd (CN) | 2017-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | ALK, ROS1, ARSA | ALK 1/4885INSR 993/4885IGF1R 507/4885 |
| US-10053477-B2 | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide | ALK, ROS1, ARSA | ALK 1/4885INSR 993/4885IGF1R 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.